ATHLONE, Ireland, March 18, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) today announced that James Tursi, M.D., has been appointed chief medical officer. Dr. Tursi will be responsible for managing all clinical development programs and medical affairs for the company.
"James is a great addition to the Innocoll team and is joining the company at a very exciting time as we advance our lead products through late stage clinical testing," said Tony Zook, chief executive officer of Innocoll. "His experience and background add significant depth and expertise to our clinical development function. James' joining Innocoll is further evidence of our progress at the company since our IPO last summer."
Dr. Tursi has extensive experience developing pharmaceuticals across a number of therapeutic areas. Most recently, as vice president of Research & Development and chief medical officer at Auxilium, he oversaw the development and regulatory approval of Xiaflex® in the U.S. and in global markets for two indications as well as moving four additional indications into advanced clinical development. Prior to his tenure at Auxilium, Dr. Tursi was responsible for medical affairs for cervical cancer vaccines in North America for GlaxoSmithKline. Dr. Tursi was also previously medical director for Proctor & Gamble Pharmaceuticals where he managed development of products in female sexual dysfunction, overactive bladder, and osteoporosis.
"Innocoll is at a transformative time in its history with three late-stage candidates and with a drug development engine based on its proprietary collagen drug formulation platform," said Dr. Tursi. "I am looking forward to working with the team to move our current assets toward the market and to developing new drug candidates that have the promise of improving patient care."
About Innocoll AG
Innocoll is a global, commercial-stage, specialty pharmaceutical company. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. The company's late-stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColl® for the treatment of post-operative pain; Cogenzia® for the adjuvant treatment of diabetic foot infections; and CollaGUARD®, a barrier for the prevention of post-surgical adhesions. The Company's approved products include: CollaGUARD, Collatamp® G, Septocoll®, RegenePro®, Collieva®, CollaCare®, Collexa®, and Zorpreva™, which are sold through strategic partnerships with various partners including Takeda, Biomet, and Jazz Pharmaceuticals.
CollaRx®, Collatamp®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Cogenzia® LidoColl®, LiquiColl®, and XaraColl® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the company.
"Any statements in this press release about our future expectations, plans and prospects, including statements about the development of our product candidates, such as the timing, conduct and results of the our Phase 3 clinical trials of XaraColl for the treatment of post-operative pain and Cogenzia for the adjuvant treatment of diabetic foot infections, and clinical studies of CollaGUARD, our barrier for the prevention of post-surgical adhesions, and the development of our other product candidates based on our proprietary collagen drug formulation platform and the sale of approved or marketed products, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including statements about the clinical trials of our product candidates. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the timing and costs involved in commercializing our products and product candidates, the initiation and conduct of clinical trials, delays in potential approvals by FDA of the commencement of trials, availability of data from clinical trials, positive results from such trials and expectations for regulatory approvals, our scientific approach and general development progress, the composition of the company's supervisory board, the availability or commercial potential of our product candidates, the sufficiency of cash resources and need for additional financing or other actions and other factors discussed in the "Risk Factors" section of the final prospectus for our IPO, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release."
CONTACT: Corporate: Denise Carter Executive Vice President Business Development and Corporate Affairs T: (215) 765-0149 E: email@example.com Investor Relations: Robert Flamm, Ph.D. Senior Vice President Russo Partners, LLC. T: (212) 845-4226 E: Robert.firstname.lastname@example.org